Toward understanding and exploiting tumor heterogen

Nature Medicine

21, 846-853

DOI: 10.1038/nm.3915

Citation Report

#	Article	IF	Citations
1	Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer. Biomarkers in Cancer, 2015, 7s1, BIC.S25247.	3.6	9
2	Defining order and timing of mutations during cancer progression: the TO-DAG probabilistic graphical model. Frontiers in Genetics, 2015, 6, 309.	1.1	9
3	Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. Oncotarget, 2015, 6, 32317-32338.	0.8	35
4	Personalized Epigenetics. , 2016, , 843-858.		2
5	Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. International Journal of Molecular Sciences, 2016, 17, 2142.	1.8	129
6	Genetic alterations in hepatocellular carcinoma: An update. World Journal of Gastroenterology, 2016, 22, 9069.	1.4	126
7	Metabolomics: Bridging the Gap between Pharmaceutical Development and Population Health. Metabolites, 2016, 6, 20.	1.3	38
8	Assessment of Tumor Heterogeneity, as Evidenced by Gene Expression Profiles, Pathway Activation, and Gene Copy Number, in Patients with Multifocal Invasive Lobular Breast Tumors. PLoS ONE, 2016, 11, e0153411.	1.1	30
9	Chromosome 8p tumor suppressor genes SH2D4A and SORBS3 cooperate to inhibit interleukinâ€6 signaling in hepatocellular carcinoma. Hepatology, 2016, 64, 828-842.	3.6	29
10	Physical and Chemical Gradients in the Tumor Microenvironment Regulate Tumor Cell Invasion, Migration, and Metastasis. Cold Spring Harbor Symposia on Quantitative Biology, 2016, 81, 189-205.	2.0	136
11	TruePrime is a novel method for whole-genome amplification from single cells based on TthPrimPol. Nature Communications, 2016, 7, 13296.	5.8	78
12	Establishing human leukemia xenograft mouse models by implanting human bone marrowâ€“like scaffold-based niches. Blood, 2016, 128, 2949-2959.	0.6	65
13	Spatial intratumoral heterogeneity of proliferation in immunohistochemical images of solid tumors. Medical Physics, 2016, 43, 2936-2947.	1.6	11
14	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy, 2016, 24, 660-661.	3.7	33
15	Intratumoral Heterogeneity of the Epigenome. Cancer Cell, 2016, 29, 440-451.	7.7	172
16	Molecular imaging in ovarian cancer. Annals of Oncology, 2016, 27, i23-i29.	0.6	5
17	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. Clinical Cancer Research, 2016, 22, 3138-3147.	3.2	68
18	Facilitating a culture of responsible and effective sharing of cancer genome data. Nature Medicine, 2016, 22, 464-471.	15.2	83

#	Article	IF	Citations
19	A framework for understanding and targeting residual disease in oncogene-driven solid cancers. Nature Medicine, 2016, 22, 472-478.	15.2	145
20	Integrating Omics Data With a Multiplex Network-Based Approach for the Identification of Cancer Subtypes. IEEE Transactions on Nanobioscience, 2016, 15, 335-342.	2.2	31
21	Precision medicine and oncology: an overview of the opportunities presented by next-generation sequencing and big data and the challenges posed to conventional drug development and regulatory approval pathways. Annals of Oncology, 2016, 27, 1644-1646.	0.6	12
22	Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current Opinion in Genetics and Development, 2016, 36, 100-106.	1.5	130
23	Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma. Blood, 2016, 127, 3127-3132.	0.6	59
24	Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium. Expert Opinion on Pharmacotherapy, 2016, 17, 1923-1936.	0.9	15
25	DNA in serum extracellular vesicles is stable under different storage conditions. BMC Cancer, 2016, 16, 753.	1.1	100
26	Genomic insights into head and neck cancer. Cancers of the Head & Neck, 2016, 1, .	6.2	65
27	High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment. Modern Pathology, 2016, 29, 1347-1357.	2.9	8
28	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. Neuro-Oncology, 2017, 19, now160.	0.6	33
29	Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy. OncoImmunology, 2016, 5, e1213934.	2.1	65
30	Challenging Roadblocks to Cancer Cure. Cancer Research, 2016, 76, 4924-4930.	0.4	3
31	scan_tcga tools for integrated epigenomic and transcriptomic analysis of tumor subgroups. Epigenomics, 2016, 8, 1315-1330.	1.0	13
32	Synthetic lethality: the road to novel therapies for breast cancer. Endocrine-Related Cancer, 2016, 23, T39-T55.	1.6	17
33	Implications and opportunities of precision medicine in rare malignancies. Expert Opinion on Orphan Drugs, 2016, 4, 953-960.	0.5	0
34	Clonal dynamics following p53 loss of heterozygosity in Kras-driven cancers. Nature Communications, 2016, 7, 12685.	5.8	58
35	Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. Nature Communications, 2016, 7, 11938.	5.8	131
36	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2016, 2, 16018.	18.1	1,863

#	Article	IF	Citations
37	Target cells for lithium in different forms within a heterogeneous hepatocarcinoma-29 population. Cell and Tissue Biology, 2016, 10, 284-289.	0.2	5
38	Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies. Genome Biology, 2016, 17, 115.	3.8	178
39	Chromatin Regulators as a Guide for Cancer Treatment Choice. Molecular Cancer Therapeutics, 2016, 15, 1768-1777.	1.9	18
40	Visualizing Clonal Evolution in Cancer. Molecular Cell, 2016, 62, 652-656.	4.5	15
41	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. Journal of Hepatology, 2016, 65, 1031-1042.	1.8	219
42	Single-cell epigenomics: powerful new methods for understanding gene regulation and cell identity. Genome Biology, 2016, 17, 72.	3.8	253
44	Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma. Gastroenterology, 2016, 150, 835-853.	0.6	1,365
45	Integrative clustering methods of multiâ€omics data for moleculeâ€based cancer classifications. Quantitative Biology, 2016, 4, 58-67.	0.3	51
46	Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nature Reviews Clinical Oncology, 2016, 13, 566-579.	12.5	38
47	DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nature Communications, 2016, 7, 10478.	5.8	195
48	Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator. Cancer Immunology Research, 2016, 4, 234-247.	1.6	74
49	Dimension reduction techniques for the integrative analysis of multi-omics data. Briefings in Bioinformatics, 2016, 17, 628-641.	3.2	280
50	Advances in computational approaches for prioritizing driver mutations and significantly mutated genes in cancer genomes. Briefings in Bioinformatics, 2016, 17, 642-656.	3.2	120
51	Decision support systems for personalized and participative radiation oncology. Advanced Drug Delivery Reviews, 2017, 109, 131-153.	6.6	113
52	Scaling single-cell genomics from phenomenology to mechanism. Nature, 2017, 541, 331-338.	13.7	633
53	Tumor evolution: Linear, branching, neutral or punctuated?. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1867, 151-161.	3.3	239
54	DNA methylation heterogeneity defines a disease spectrum in Ewing sarcoma. Nature Medicine, 2017, 23, 386-395.	15.2	193
55	Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease. Cell Stem Cell, 2017, 20, 329-344.e7.	5.2	101

#	Article	IF	Citations
56	Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer. Nature Genetics, 2017, 49, 358-366.	9.4	316
57	DNA copy number changes define spatial patterns of heterogeneity in colorectal cancer. Nature Communications, 2017, 8, 14093.	5.8	85
58	Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications. Current Breast Cancer Reports, 2017, 9, 34-44.	0.5	11
59	Biologically Relevant Heterogeneity: Metrics and Practical Insights. SLAS Discovery, 2017, 22, 213-237.	1.4	65
60	Ex vivo tumor culture systems for functional drug testing and therapy response prediction. Future Science OA, 2017, 3, FSO190.	0.9	117
61	EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nature Reviews Clinical Oncology, 2017, 14, 611-629.	12.5	1,865
62	The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. Expert Review of Molecular Diagnostics, 2017, 17, 557-566.	1.5	18
63	Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia. Nature Medicine, 2017, 23, 692-702.	15.2	336
64	Pathogenesis of lymphomas. , 2017, , 11-31.		2
65	Rethinking cancer nanotheranostics. Nature Reviews Materials, 2017, 2, .	23.3	860
66	Mass Spectrometry Imaging for the Investigation of Intratumor Heterogeneity. Advances in Cancer Research, 2017, 134, 201-230.	1.9	23
67	Quadruplex nucleic acids as targets for anticancer therapeutics. Nature Reviews Chemistry, 2017, 1, .	13.8	357
68	Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia. Leukemia, 2017, 31, 2577-2586.	3.3	31
69	DNA methylation: an epigenetic mark of cellular memory. Experimental and Molecular Medicine, 2017, 49, e322-e322.	3.2	286
71	Single-Cell Genomics Unravels Brain Cell-Type Complexity. Advances in Experimental Medicine and Biology, 2017, 978, 393-407.	0.8	5
72	Genetic background and evolution of relapses in aggressive B-cell lymphomas. Haematologica, 2017, 102, 1139-1149.	1.7	18
74	Molecular Profiling and Significance of Circulating Tumor Cell Based Genetic Signatures. Advances in Experimental Medicine and Biology, 2017, 994, 143-167.	0.8	3
75	Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance. Drug Resistance Updates, 2017, 31, 15-30.	6.5	242

#	Article	IF	Citations
77	Single-cell genomic profiling of acute myeloid leukemia for clinical use: A pilot study. Oncology Letters, 2017, 13, 1625-1630.	0.8	13
78	Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy. Pharmacological Research, 2017, 126, 66-76.	3.1	28
79	Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Scientific Reports, 2017, 7, 44206.	1.6	28
80	CRISPR/Cas9 editing of the genome for cancer modeling. Methods, 2017, 121-122, 130-137.	1.9	34
81	Liver Cancer Cell of Origin, Molecular Class, and Effects onÂPatient Prognosis. Gastroenterology, 2017, 152, 745-761.	0.6	838
82	Implementation of a Multicenter Biobanking Collaboration for Nextâ€Generation Sequencingâ€Based Biomarker Discovery Based on Fresh Frozen Pretreatment Tumor Tissue Biopsies. Oncologist, 2017, 22, 33-40.	1.9	29
83	Immunophenotyping and Transcriptomic Outcomes in PDX-Derived TNBC Tissue. Molecular Cancer Research, 2017, 15, 429-438.	1.5	9
84	Preclinical mouse solid tumour models: status quo, challenges and perspectives. Nature Reviews Cancer, 2017, 17, 751-765.	12.8	222
85	Not only P-glycoprotein: Amplification of the ABCB1- containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins. Drug Resistance Updates, 2017, 32, 23-46.	6.5	109
86	SCENIC: single-cell regulatory network inference and clustering. Nature Methods, 2017, 14, 1083-1086.	9.0	3,086
87	Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space. Clinical Cancer Research, 2017, 23, 7641-7649.	3.2	22
88	Signature of genetic associations in oral cancer. Tumor Biology, 2017, 39, 101042831772592.	0.8	26
89	Zinc and its transporter ZIP6 are key mediators of breast cancer cell survival under high glucose conditions. FEBS Letters, 2017, 591, 3348-3359.	1.3	24
90	Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma. Journal of Hepatology, 2017, 67, 1222-1231.	1.8	121
91	Imaging Tunneling Membrane Tubes Elucidates Cell Communication in Tumors. Trends in Cancer, 2017, 3, 678-685.	3.8	38
92	Classifying the evolutionary and ecological features of neoplasms. Nature Reviews Cancer, 2017, 17, 605-619.	12.8	303
93	Bridging Bioâ€“Nano Science and Cancer Nanomedicine. ACS Nano, 2017, 11, 9594-9613.	7.3	304
94	Fatty acid synthase (FASN) as a therapeutic target in breast cancer. Expert Opinion on Therapeutic Targets, 2017, 21, 1001-1016.	1.5	185

#	Article	IF	Citations
95	A computational multiscale agent-based model for simulating spatio-temporal tumour immune response to PD1 and PDL1 inhibition. Journal of the Royal Society Interface, 2017, 14, 20170320.	1.5	118
96	Somatic Mutation Analysis of Human Cancers: Challenges in Clinical Practice. Journal of Clinical Pharmacology, 2017, 57, S60-S66.	1.0	4
97	Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?. Archives of Gynecology and Obstetrics, 2017, 296, 1055-1062.	0.8	49
98	Precision Oncology: The Road Ahead. Trends in Molecular Medicine, 2017, 23, 874-898.	3.5	131
99	Exploring Metabolic Configurations of Single Cells within Complex Tissue Microenvironments. Cell Metabolism, 2017, 26, 788-800.e6.	7.2	81
100	Investigating the Robustness Neighborhood Gray Tone Difference Matrix and Gray Level Co-occurrence Matrix Radiomic Features on Clinical Computed Tomography Systems Using Anthropomorphic Phantoms. Journal of Computer Assisted Tomography, 2017, 41, 995-1001.	0.5	15
101	Variation in organâ€specific PIK3CA and KRAS mutant levels in normal human tissues correlates with mutation prevalence in corresponding carcinomas. Environmental and Molecular Mutagenesis, 2017, 58, 466-476.	0.9	16
102	Precision medicine: the foundation of future cancer therapeutics. Npj Precision Oncology, 2017, 1, 12.	2.3	82
103	Improving the prediction of overall survival for head and neck cancer patients using image biomarkers in combination with clinical parameters. Radiotherapy and Oncology, 2017, 124, 256-262.	0.3	45
104	Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. Cancer Research, 2017, 77, 5687-5698.	0.4	112
105	Mechanisms that drive inflammatory tumor microenvironment, tumor heterogeneity, and metastatic progression. Seminars in Cancer Biology, 2017, 47, 185-195.	4.3	114
106	Genetics of Hepatocellular Carcinoma: Risk Stratification, Clinical Outcome, and Implications for Therapy. Digestive Disease Interventions, 2017, 01, 055-065.	0.3	2
107	Targeted therapies for renal cell carcinoma. Nature Reviews Nephrology, 2017, 13, 496-511.	4.1	185
108	A comparison of reference-based algorithms for correcting cell-type heterogeneity in Epigenome-Wide Association Studies. BMC Bioinformatics, 2017, 18, 105.	1.2	297
109	Extracellular vesicles in gastrointestinal cancer in conjunction with microbiota: On the border of Kingdoms. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 372-393.	3.3	35
110	Genome evolution in ductal carcinoma in situ: invasion of the clones. Journal of Pathology, 2017, 241, 208-218.	2.1	70
111	Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer. Seminars in Cell and Developmental Biology, 2017, 64, 98-106.	2.3	43
112	Cancer heterogeneity and imaging. Seminars in Cell and Developmental Biology, 2017, 64, 48-57.	2.3	39

#	Article	IF	Citations
113	Blocking SIAH Proteolysis, an Important K-RAS Vulnerability, to Control and Eradicate K-RAS-Driven Metastatic Cancer. , 2017, , 213-232.		4
114	Drug-Triggered Self-Assembly of Linear Polymer into Nanoparticles for Simultaneous Delivery of Hydrophobic and Hydrophilic Drugs in Breast Cancer Cells. ACS Omega, 2017, 2, 8730-8740.	1.6	13
115	Immunotherapy for Pediatric Brain Tumors. Brain Sciences, 2017, 7, 137.	1.1	24
116	Detection of Intratumor Heterogeneity in Modern Pathology: A Multisite Tumor Sampling Perspective. Frontiers in Medicine, 2017, 4, 25.	1.2	11
117	Automated Generation of Reliable Blood Velocity Parameter Maps from Contrast-Enhanced Ultrasound Data. Contrast Media and Molecular Imaging, 2017, 2017, 1-8.	0.4	5
118	Manipulation of Innate and Adaptive Immunity through Cancer Vaccines. Journal of Immunology Research, 2017, 2017, 1-7.	0.9	31
119	An Introduction to Radiomics: An Evolving Cornerstone of Precision Medicine. , 2017, , 223-245.		4
120	Racial disparity in metabolic regulation of cancer. Frontiers in Bioscience - Landmark, 2017, 22, 1221-1246.	3.0	5
121	Cancer Metabolism and Tumor Heterogeneity: Imaging Perspectives Using MR Imaging and Spectroscopy. Contrast Media and Molecular Imaging, 2017, 2017, 1-18.	0.4	39
122	Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment. Cancers, 2017, 9, 35.	1.7	85
123	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	0.8	9
124	Role of CXC group chemokines in lung cancer development and progression. Journal of Thoracic Disease, 2017, 9, S164-S171.	0.6	53
125	Challenges and unanswered questions for the next decade of circulating tumour cell research in lung cancer. Translational Lung Cancer Research, 2017, 6, 454-472.	1.3	27
126	Tumor Evolution, Heterogeneity, and Therapy for Our Patients With Advanced Cancer: How Far Have We Come?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, e8-e15.	1.8	13
127	Cancer metastasis - tricks of the trade. Bosnian Journal of Basic Medical Sciences, 2017, 17, 172-182.	0.6	82
128	Light-Activated Coreâ€“Shell Nanoparticles for Spatiotemporally Specific Treatment of Metastatic Triple-Negative Breast Cancer. ACS Nano, 2018, 12, 2789-2802.	7.3	64
129	Y1 receptor ligand-based nanomicelle as a novel nanoprobe for glioma-targeted imaging and therapy. Nanoscale, 2018, 10, 5845-5851.	2.8	14
130	Biobanking in Precision Medicine. Current Pharmacology Reports, 2018, 4, 91-101.	1.5	5

#	Article	IF	Citations
131	Genomic Profiling and Metabolic Homeostasis in Primary Liver Cancers. Trends in Molecular Medicine, 2018, 24, 395-411.	3.5	58
132	Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. Journal of Controlled Release, 2018, 277, 1-13.	4.8	214
133	Genomics and emerging biomarkers for immunotherapy of colorectal cancer. Seminars in Cancer Biology, 2018, 52, 189-197.	4.3	112
134	Hepatocellular carcinoma: Present and future. Medicina ClÃnica (English Edition), 2018, 150, 390-397.	0.1	14
135	NIT1 suppresses tumour proliferation by activating the TGFÎ²1â€“Smad2/3 signalling pathway in colorectal cancer. Cell Death and Disease, 2018, 9, 263.	2.7	19
136	Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression. Nature Communications, 2018, 9, 389.	5.8	98
137	Application of single-cell sequencing in human cancer. Briefings in Functional Genomics, 2018, 17, 273-282.	1.3	34
138	cHCCâ€CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	3.6	244
139	Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development. OMICS A Journal of Integrative Biology, 2018, 22, 17-34.	1.0	40
140	Network science in clinical trials: A patient-centered approach. Seminars in Cancer Biology, 2018, 52, 135-150.	4.3	9
141	Proteome Heterogeneity in Colorectal Cancer. Proteomics, 2018, 18, 1700169.	1.3	13
142	Super-Resolution Imaging With Ultrafast Ultrasound Imaging of Optically Triggered Perfluorohexane Nanodroplets. IEEE Transactions on Ultrasonics, Ferroelectrics, and Frequency Control, 2018, 65, 2277-2285.	1.7	27
143	¹⁸F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. Journal of Nuclear Medicine, 2018, 59, 1212-1218.	2.8	45
144	Future of Liquid Biopsies With Growing Technological and Bioinformatics Studies: Opportunities and Challenges in Discovering Tumor Heterogeneity With Single-Cell Level Analysis. Cancer Journal (Sudbury, Mass), 2018, 24, 104-108.	1.0	34
145	A new method for the high-precision assessment of tumor changes in response to treatment. Bioinformatics, 2018, 34, 2625-2633.	1.8	4
146	Size shrinkable drug delivery nanosystems and priming the tumor microenvironment for deep intratumoral penetration of nanoparticles. Journal of Controlled Release, 2018, 277, 35-47.	4.8	113
147	Tumor Heterogeneity: Will It Change What Pathologists Do. Pathobiology, 2018, 85, 18-22.	1.9	10
148	Epigenetic regulation of gene expression in cancer: techniques, resources and analysis. Briefings in Functional Genomics, 2018, 17, 49-63.	1.3	111

#	Article	IF	Citations
149	New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis. Advances in Anatomic Pathology, 2018, 25, 131-142.	2.4	37
150	Single cell analysis of normal and leukemic hematopoiesis. Molecular Aspects of Medicine, 2018, 59, 85-94.	2.7	53
151	Carcinoma hepatocelular: presente y futuro. Medicina ClÃnica, 2018, 150, 390-397.	0.3	35
152	Circulating tumor DNA: an important tool in precision medicine for lymphoma. Expert Review of Precision Medicine and Drug Development, 2018, 3, 11-21.	0.4	4
153	Modulating secreted components of tumor microenvironment: A masterstroke in tumor therapeutics. Cancer Biology and Therapy, 2018, 19, 3-12.	1.5	51
154	Royal Society Scientific Meeting: Extracellular vesicles in the tumour microenvironment. Philosophical Transactions of the Royal Society B: Biological Sciences, 2018, 373, 20170066.	1.8	11
155	Time for change: a new training programme for morpho-molecular pathologists?. Journal of Clinical Pathology, 2018, 71, 285-290.	1.0	21
156	Joint Principal Trend Analysis for Longitudinal High-dimensional Data. Biometrics, 2018, 74, 430-438.	0.8	4
157	Epigenetic drivers of tumourigenesis and cancer metastasis. Seminars in Cancer Biology, 2018, 51, 149-159.	4.3	246
158	Emerging Potential of Cancer Therapyâ€"Binary Direct Interactions of Cancer and Stromal Cells. Russian Journal of Genetics, 2018, 54, 1416-1428.	0.2	0
159	Deep Subspace Similarity Fusion for the Prediction of Cancer Subtypes. , 2018, , .		3
160	Integrative Molecular Tumor Classification: A Pathologist's View. , 2018, , 279-279.		0
161	Subclonal evolution of pulmonary adenocarcinomas delineated by spatially distributed somatic mitochondrial mutations. Lung Cancer, 2018, 126, 80-88.	0.9	16
162	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. Cancer Cell, 2018, 34, 1012-1026.e3.	7.7	209
163	Oxygen Production of Modified Coreâ€"Shell CuO@ZrO‹sub›2‹/sub› Nanocomposites by Microwave Radiation to Alleviate Cancer Hypoxia for Enhanced Chemo-Microwave Thermal Therapy. ACS Nano, 2018, 12, 12721-12732.	7.3	92
164	Zinc Transporters and the Progression of Breast Cancers. Biological and Pharmaceutical Bulletin, 2018, 41, 1517-1522.	0.6	40
165	Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes. Clinical Cancer Research, 2019, 25, 463-472.	3.2	41
166	WHEN RELAXATION MEETS ADAPTATION IN COMPLEX ADAPTIVE SYSTEMS: A COMPUTATIONAL STUDY OF TUMORIGENESIS. International Journal of Modeling, Simulation, and Scientific Computing, 2018, 21, 1750016.	0.9	1

#	Article	IF	Citations
167	Towards quantitative and multiplexed in vivo functional cancer genomics. Nature Reviews Genetics, 2018, 19, 741-755.	7.7	45
168	Heterogeneity in Colorectal Primary Tumor and Synchronous Liver Metastases. Russian Journal of Genetics, 2018, 54, 698-702.	0.2	2
169	Computational fluid dynamics with imaging of cleared tissue and of in vivo perfusion predicts drug uptake and treatment responses in tumours. Nature Biomedical Engineering, 2018, 2, 773-787.	11.6	91
170	Development and validation of an immunity-related classifier of nine chemokines for predicting recurrence in stage I-III patients with colorectal cancer after operation. Cancer Management and Research, 2018, Volume 10, 4051-4064.	0.9	6
171	Overcoming multiple drug resistance in cancer using polymeric micelles. Expert Opinion on Drug Delivery, 2018, 15, 1127-1142.	2.4	39
172	Application of Radiomics and Decision Support Systems for Breast MR Differential Diagnosis. Computational and Mathematical Methods in Medicine, 2018, 2018, 1-8.	0.7	22
173	Cells with stemness features are generated from in vitro transformed human fibroblasts. Scientific Reports, 2018, 8, 13838.	1.6	8
174	Oncogenic transformation of normal breast epithelial cells co-cultured with cancer cells. Cell Cycle, 2018, 17, 2027-2040.	1.3	10
175	Multi-region proteome analysis quantifies spatial heterogeneity of prostate tissue biomarkers. Life Science Alliance, 2018, 1, e201800042.	1.3	51
176	Personalized disease signatures through information-theoretic compaction of big cancer data. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 7694-7699.	3.3	27
177	Future Challenges and Prospects for the Role of Epigenetic Mechanisms in Cancer Management. , 2018, , 345-372.		0
178	A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. European Journal of Cancer, 2018, 101, 143-151.	1.3	15
179	The role of metabolism and tunneling nanotube-mediated intercellular mitochondria exchange in cancer drug resistance. Biochemical Journal, 2018, 475, 2305-2328.	1.7	73
180	Simulating heterogeneous populations using Boolean models. BMC Systems Biology, 2018, 12, 64.	3.0	1
181	Robustness and evolvability of heterogeneous cell populations. Molecular Biology of the Cell, 2018, 29, 1400-1409.	0.9	11
182	Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance. Essays in Biochemistry, 2018, 62, 583-593.	2.1	25
183	Radiomic analysis of contrast-enhanced ultrasound data. Scientific Reports, 2018, 8, 11359.	1.6	31
184	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	3.6	17

#	Article	IF	Citations
185	Advances in Tumor Targeted Liposomes. Current Molecular Medicine, 2018, 18, 44-57.	0.6	51
186	A comparison of next-generation sequencing analysis methods for cancer xenograft samples. Journal of Genetics and Genomics, 2018, 45, 345-350.	1.7	5
187	Timing somatic events in the evolution of cancer. Genome Biology, 2018, 19, 95.	3.8	69
188	Non-invasive monitoring of diffuse large B-cell lymphoma by cell-free DNA high-throughput targeted sequencing: analysis of a prospective cohort. Blood Cancer Journal, 2018, 8, 74.	2.8	67
189	Mutual concessions and compromises between stromal cells and cancer cells: driving tumor development and drug resistance. Cellular Oncology (Dordrecht), 2018, 41, 353-367.	2.1	64
190	Self-Assembled Glycosylated Chalconeâ€“Boronic Acid Nanodrug Exhibits Anticancer Activity through Mitochondrial Impairment. ACS Applied Bio Materials, 2018, 1, 347-355.	2.3	0
191	Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity. Frontiers in Cell and Developmental Biology, 2018, 6, 44.	1.8	38
192	Single-Cell (Multi)omics Technologies. Annual Review of Genomics and Human Genetics, 2018, 19, 15-41.	2.5	149
193	NHERF1 and tumor microenvironment: a new scene in invasive breast carcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 96.	3.5	16
194	Applications of Flavonoids, With an Emphasis on Hesperidin, as Anticancer Prodrugs: Phytotherapy as an Alternative to Chemotherapy. Studies in Natural Products Chemistry, 2018, , 161-212.	0.8	13
195	Targeting molecular pathways in cancer stem cells by natural bioactive compounds. Pharmacological Research, 2018, 135, 150-165.	3.1	60
196	Molecular Targets in Hepatocarcinogenesis and Implications for Therapy. Journal of Clinical Medicine, 2018, 7, 213.	1.0	24
197	Blocking the FSTL1-DIP2A Axis Improves Anti-tumor Immunity. Cell Reports, 2018, 24, 1790-1801.	2.9	35
198	Cancer vaccine: learning lessons from immune checkpoint inhibitors. Journal of Cancer, 2018, 9, 263-268.	1.2	38
199	Biphenotypic Primary Liver Carcinoma. , 2018, , 665-669.		1
200	Chemotherapy-Induced Tunneling Nanotubes Mediate Intercellular Drug Efflux in Pancreatic Cancer. Scientific Reports, 2018, 8, 9484.	1.6	79
201	Intratumor Heterogeneity and Circulating Tumor Cell Clusters. Molecular Biology and Evolution, 2018, 35, 2135-2144.	3.5	16
202	Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer. European Radiology, 2019, 29, 411-421.	2.3	22

#	Article	IF	Citations
203	Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma. BMC Cancer, 2019, 19, 786.	1.1	12
204	Antifolate SERS-active nanovectors: quantitative drug nanostructuring and selective cell targeting for effective theranostics. Nanoscale, 2019, 11, 15224-15233.	2.8	12
205	Targeting self- and neoepitopes with a modular self-adjuvanting cancer vaccine. JCI Insight, 2019, 4, .	2.3	28
206	Deep learning with multimodal representation for pancancer prognosis prediction. Bioinformatics, 2019, 35, i446-i454.	1.8	215
207	Systems-Level Understanding of Single-Cell Omics. , 2019, , 433-456.		0
208	A reignited debate over the cell(s) of origin for glioblastoma and its clinical implications. Frontiers of Medicine, 2019, 13, 531-539.	1.5	26
209	Graphene Oxide Supported Liposomes as Red Emissive Theranostics for Phototriggered Tissue Visualization and Tumor Regression. ACS Applied Bio Materials, 2019, 2, 3312-3320.	2.3	30
210	Highly Multiplexed, Quantitative Tissue Imaging at Cellular Resolution. Current Pathobiology Reports, 2019, 7, 109-118.	1.6	2
211	Detection of mutational patterns in cellâ€free DNA of colorectal cancer by custom amplicon sequencing. Molecular Oncology, 2019, 13, 1669-1683.	2.1	8
212	PhISCS: a combinatorial approach for subperfect tumor phylogeny reconstruction via integrative use of single-cell and bulk sequencing data. Genome Research, 2019, 29, 1860-1877.	2.4	73
213	Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer. BMC Cancer, 2019, 19, 1030.	1.1	31
214	Epigenetic heterogeneity in cancer. Biomarker Research, 2019, 7, 23.	2.8	145
215	Cell-free DNA and the monitoring of lymphoma treatment. Pharmacogenomics, 2019, 20, 1271-1282.	0.6	6
216	Evolution and Impact of Subclonal Mutations in Papillary Thyroid Cancer. American Journal of Human Genetics, 2019, 105, 959-973.	2.6	22
217	Inferring subgroup-specific driver genes from heterogeneous cancer samples via subspace learning with subgroup indication. Bioinformatics, 2020, 36, 1855-1863.	1.8	53
218	Tumor BRCA Test for Patients with Epithelial Ovarian Cancer: The Role of Molecular Pathology in the Era of PARP Inhibitor Therapy. Cancers, 2019, 11, 1641.	1.7	22
219	Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells. Nature Reviews Cancer, 2019, 19, 553-567.	12.8	393
220	Addressing Patient Specificity in the Engineering of Tumor Models. Frontiers in Bioengineering and Biotechnology, 2019, 7, 217.	2.0	53

#	Article	IF	Citations
221	Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts. Journal of Thoracic Oncology, 2019, 14, 1935-1947.	0.5	69
222	Liquid biopsy: one cell at a time. Npj Precision Oncology, 2019, 3, 23.	2.3	72
223	Designing highly crystalline multifunctional multicolor-luminescence nanosystem for tracking breast cancer heterogeneity. Nanoscale Advances, 2019, 1, 1021-1034.	2.2	6
224	Finite mixture of varying coefficient model: Estimation and component selection. Journal of Multivariate Analysis, 2019, 171, 452-474.	0.5	5
225	Precision Medicine in Cancer Therapy. Cancer Treatment and Research, 2019, , .	0.2	4
226	Use of Precision Imaging in the Evaluation of Pancreas Cancer. Cancer Treatment and Research, 2019, 178, 209-236.	0.2	10
227	Liquid biopsy in nonâ€Hodgkin's lymphoma. Hematological Oncology, 2019, 37, 70-74.	0.8	15
228	Systematic expression analysis of ligand-receptor pairs reveals important cell-to-cell interactions inside glioma. Cell Communication and Signaling, 2019, 17, 48.	2.7	31
229	Vomocytosis by macrophages: a crucial event in the local niche of tumors. Future Oncology, 2019, 15, 1545-1550.	1.1	3
230	Contribution of Epithelial Plasticity to Therapy Resistance. Journal of Clinical Medicine, 2019, 8, 676.	1.0	42
231	Immunoprofiling of Breast Cancer Antigens Using Antibodies Derived from Local Lymph Nodes. Cancers, 2019, 11, 682.	1.7	10
232	Advances in the Profiling of Singleâ€Cell DNA Modifications. Small Methods, 2019, 3, 1900137.	4.6	4
233	Natural Selection Between Two Games with Applications to Game Theoretical Models of Cancer. Bulletin of Mathematical Biology, 2019, 81, 2117-2132.	0.9	7
234	Germline Predisposition and Copy Number Alteration in Pre-stage Lung Adenocarcinomas Presenting as Ground-Glass Nodules. Frontiers in Oncology, 2019, 9, 288.	1.3	16
235	Colloids, nanoparticles, and materials for imaging, delivery, ablation, and theranostics by focused ultrasound (FUS). Theranostics, 2019, 9, 2572-2594.	4.6	42
236	State of the Art and Future Direction for the Analysis of Cell-Free Circulating DNA. , 2019, , 133-188.		2
237	Preclinical models in ovarian cancer. , 2019, , 31-57.		0
238	Porcine Models of Pancreatic Cancer. Frontiers in Oncology, 2019, 9, 144.	1.3	30

#	Article	IF	Citations
239	The Impact of Heterogeneity on Single-Cell Sequencing. Frontiers in Genetics, 2019, 10, 8.	1.1	84
240	Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Digestive Diseases and Sciences, 2019, 64, 1016-1029.	1.1	25
241	Glucocorticoids promote breast cancer metastasis. Nature, 2019, 567, 540-544.	13.7	289
242	The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients. Cancers, 2019, 11, 341.	1.7	52
243	Polytherapy and Targeted Cancer Drug Resistance. Trends in Cancer, 2019, 5, 170-182.	3.8	183
244	RnBeads 2.0: comprehensive analysis of DNA methylation data. Genome Biology, 2019, 20, 55.	3.8	223
245	Intratumor heterogeneity index of breast carcinomas based on DNA methylation profiles. BMC Cancer, 2019, 19, 328.	1.1	6
246	Detection of Solid Tumor Molecular Residual DiseaseÂ(MRD) Using Circulating Tumor DNA (ctDNA). Molecular Diagnosis and Therapy, 2019, 23, 311-331.	1.6	123
247	Recent advances in the metabolomic study of bladder cancer. Expert Review of Proteomics, 2019, 16, 315-324.	1.3	28
248	Probing glioblastoma and its microenvironment using single-nucleus and single-cell sequencing. , 2019, , .		1
249	Integrating Multi-Omic Data with Deep Subspace Fusion Clustering for Cancer Subtype Prediction. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 18, 1-1.	1.9	11
250	Addressing cellular heterogeneity in tumor and circulation for refined prognostication. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17957-17962.	3.3	51
251	Prognostic implications of 5-hydroxymethylcytosines from circulating cell-free DNA in diffuse large B-cell lymphoma. Blood Advances, 2019, 3, 2790-2799.	2.5	36
252	pMHC Structural Comparisons as a Pivotal Element to Detect and Validate T-Cell Targets for Vaccine Development and Immunotherapyâ€"A New Methodological Proposal. Cells, 2019, 8, 1488.	1.8	3
253	Translating current biomedical therapies for long duration, deep space missions. Precision Clinical Medicine, 2019, 2, 259-269.	1.3	24
254	Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor Microenvironment. Theranostics, 2019, 9, 8073-8090.	4.6	226
255	CDSeq: A novel complete deconvolution method for dissecting heterogeneous samples using gene expression data. PLoS Computational Biology, 2019, 15, e1007510.	1.5	42
256	Overcoming Physiological Barriers to Nanoparticle Deliveryâ€"Are We There Yet?. Frontiers in Bioengineering and Biotechnology, 2019, 7, 415.	2.0	81

#	Article	IF	Citations
257	Utilization of optically induced dielectrophoresis in a microfluidic system for sorting and isolation of cells with varied degree of viability: Demonstration of the sorting and isolation of drug-treated cancer cells with various degrees of anti-cancer drug resistance gene expression. Sensors and Actuators B: Chemical, 2019, 283, 621-631.	4.0	44
258	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145
259	Design and Demonstration of a Configurable Imaging Platform for Combined Laser, Ultrasound, and Elasticity Imaging. IEEE Transactions on Medical Imaging, 2019, 38, 1622-1632.	5.4	10
260	Quantitative Characterization of CD8+ T Cell Clustering and Spatial Heterogeneity in Solid Tumors. Frontiers in Oncology, 2018, 8, 649.	1.3	30
261	Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer. Neoplasia, 2019, 21, 17-29.	2.3	20
262	Live single cell mass spectrometry reveals cancerâ€specific metabolic profiles of circulating tumor cells. Cancer Science, 2019, 110, 697-706.	1.7	90
263	The shrinking scope of pragmatic trials: a methodological reflection on their domain of applicability. Journal of Clinical Epidemiology, 2019, 107, 71-76.	2.4	7
264	Integration of fluorescence imaging and electrochemical biosensing for both qualitative location and quantitative detection of cancer cells. Biosensors and Bioelectronics, 2019, 130, 132-138.	5.3	59
265	Emerging transporter-targeted nanoparticulate drug delivery systems. Acta Pharmaceutica Sinica B, 2019, 9, 49-58.	5.7	51
266	Clonal evolution through genetic bottlenecks and telomere attrition: Potential threats to in vitro data reproducibility. Genes Chromosomes and Cancer, 2019, 58, 452-461.	1.5	15
267	Precision medicine needs pioneering clinical bioinformaticians. Briefings in Bioinformatics, 2019, 20, 752-766.	3.2	40
268	Constructing Pathway-Based Priors within a Gaussian Mixture Model for Bayesian Regression and Classification. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2019, 16, 524-537.	1.9	23
269	In Silico implementation of evolutionary paradigm in therapy design: Towards anti-cancer therapy as Darwinian process. Journal of Theoretical Biology, 2020, 485, 110038.	0.8	1
270	Tumor Liquid Biopsies. Recent Results in Cancer Research, 2020, , .	1.8	11
271	Immunotherapeutic Transport Oncophysics: Space, Time, and Immune Activation in Cancer. Trends in Cancer, 2020, 6, 40-48.	3.8	12
272	Modeling Tumor Evolutionary Dynamics to Predict Clinical Outcomes for Patients with Metastatic Colorectal Cancer: A Retrospective Analysis. Cancer Research, 2020, 80, 591-601.	0.4	13
273	A rewiring model of intratumoral interaction networks. Computational and Structural Biotechnology Journal, 2020, 18, 45-51.	1.9	3
274	Precision medicine in an imprecise and complex world: Magic bullets, hype, and the fuzzy line between health and disease. Journal of Evaluation in Clinical Practice, 2020, 26, 1534-1538.	0.9	5

#	Article	IF	Citations
275	The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review. Cancers, 2020, 12, 2808.	1.7	33
276	DNA Nanostructures and DNAâ€Functionalized Nanoparticles for Cancer Theranostics. Advanced Science, 2020, 7, 2001669.	5.6	47
277	Tumorâ€Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity. Advanced Materials, 2020, 32, e2002197.	11.1	78
278	Murine models of IDH-wild-type glioblastoma exhibit spatial segregation of tumor initiation and manifestation during evolution. Nature Communications, 2020, 11, 3669.	5.8	14
279	PhISCS-BnB: a fast branch and bound algorithm for the perfect tumor phylogeny reconstruction problem. Bioinformatics, 2020, 36, i169-i176.	1.8	19
280	Mitochondria-targeted nanospheres with deep tumor penetration for photo/starvation therapy. Journal of Materials Chemistry B, 2020, 8, 7740-7754.	2.9	19
281	Shortwave infrared emitting multicolored nanoprobes for biomarker-specific cancer imaging in vivo. BMC Cancer, 2020, 20, 1082.	1.1	5
282	A Multi-Source Data Fusion Framework for Revealing the Regulatory Mechanism of Breast Cancer Immune Evasion. Frontiers in Genetics, 2020, 11, 595324.	1.1	3
283	Tumor-Microenvironment- Responsive Size-Shrinkable Drug-Delivery Nanosystems for Deepened Penetration Into Tumors. Frontiers in Molecular Biosciences, 2020, 7, 576420.	1.6	25
284	Imaging Mass Spectrometry Reveals Tumor Metabolic Heterogeneity. IScience, 2020, 23, 101355.	1.9	17
285	NIR Photodynamic Destruction of PDAC and HNSCC Nodules Using Triple-Receptor-Targeted Photoimmuno-Nanoconjugates: Targeting Heterogeneity in Cancer. Journal of Clinical Medicine, 2020, 9, 2390.	1.0	20
286	Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies. Cancers, 2020, 12, 2392.	1.7	171
287	Selfâ€Assembled GO Honeycomb Microarray for Selective Cancer Cell Capture and Single Cell Analysis of Proteolytic Expression. Advanced Healthcare Materials, 2020, 9, e2001006.	3.9	8
288	Systematic Assessment of Tumor Purity and Its Clinical Implications. JCO Precision Oncology, 2020, 4, 995-1005.	1.5	23
289	Methods for copy number aberration detection from single-cell DNA-sequencing data. Genome Biology, 2020, 21, 208.	3.8	72
290	A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles from Culture Supernatant of Human Ovarian Cancer Cell Line A2780 and Body Fluids of High-Grade Serous Carcinoma Patients . Cancer Management and Research, 2020, Volume 12, 6291-6301.	0.9	7
291	CRISPR and transposon in vivo screens for cancer drivers and therapeutic targets. Genome Biology, 2020, 21, 204.	3.8	14
292	Ab initio spillover compensation in mass cytometry data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2020, 99, 899-909.	1.1	10

#	Article	IF	Citations
293	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 33295-33304.	3.3	37
294	Sinusoidal Endothelial Cell Progenitor Cells Promote Tumour Progression in Patients with Hepatocellular Carcinoma. Stem Cells International, 2020, 2020, 1-12.	1.2	1
295	Improving existing analysis pipeline to identify and analyze cancer driver genes using multi-omics data. Scientific Reports, 2020, 10, 20521.	1.6	10
296	Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy. Frontiers in Oncology, 2020, 10, 586580.	1.3	42
297	Multi-Omics Analysis Detects Novel Prognostic Subgroups of Breast Cancer. Frontiers in Genetics, 2020, 11, 574661.	1.1	18
298	Immunotherapy for Medulloblastoma: Current Perspectives . ImmunoTargets and Therapy, 2020, Volume 9, 57-77.	2.7	33
299	Fitness and Productivity Increase with Ecotypic Diversity among Escherichia coli Strains That Coevolved in a Simple, Constant Environment. Applied and Environmental Microbiology, 2020, 86, .	1.4	16
300	Use of inkjet-printed single cells to quantify intratumoral heterogeneity. Biofabrication, 2020, 12, 035030.	3.7	22
301	Autologously Humanized Mice for Immuneâ€Oncologic Studies. Current Protocols in Pharmacology, 2020, 89, e76.	4.0	4
302	Bioprinting of in vitro tumor models for personalized cancer treatment: a review. Biofabrication, 2020, 12, 042001.	3.7	61
303	Strategic Combinations to Prevent and Overcome Resistance to Targeted Therapies in Oncology. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2020, 40, e292-e308.	1.8	3
304	The genomic landscape of metastasis in treatment-naÃ¯ve breast cancer models. PLoS Genetics, 2020, 16, e1008743.	1.5	17
305	Targeting the Tumor Core: Hypoxia-Responsive Nanoparticles for the Delivery of Chemotherapy to Pancreatic Tumors. Molecular Pharmaceutics, 2020, 17, 2849-2863.	2.3	40
306	Newcastle Disease Virus (NDV) Oncolytic Activity in Human Glioma Tumors Is Dependent on CDKN2A-Type I IFN Gene Cluster Codeletion. Cells, 2020, 9, 1405.	1.8	20
307	Examining treatment responses of diagnostic marrow in murine xenografts to predict relapse in children with acute lymphoblastic leukaemia. British Journal of Cancer, 2020, 123, 742-751.	2.9	1
308	Functional smart hybrid nanostructures based nanotheranostic approach for advanced cancer treatment. Applied Surface Science, 2020, 527, 146809.	3.1	26
309	Impact of tumor heterogeneity and tissue sampling for genetic mutation testing: a systematic review and post hoc analysis. Journal of Clinical Epidemiology, 2020, 126, 45-55.	2.4	6
310	Identification of Radioresponsive Genes in Esophageal Cancer from Longitudinal and Single Cell Exome Sequencing. International Journal of Radiation Oncology Biology Physics, 2020, 108, 1103-1114.	0.4	11

#	Article	IF	Citations
311	Profiling DNA mutation patterns by SERS fingerprinting for supervised cancer classification. Biosensors and Bioelectronics, 2020, 165, 112392.	5.3	32
312	Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T-cell lymphoma. Blood Advances, 2020, 4, 2392-2403.	2.5	11
313	Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin. Frontiers in Genetics, 2020, 11, 426.	1.1	3
314	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. Frontiers in Oncology, 2020, 10, 899.	1.3	44
315	Bibliogrpahy. , 2020, , 327-335.		0
316	Imaging Cell Death: Focus on Early Evaluation of Tumor Response to Therapy. Bioconjugate Chemistry, 2020, 31, 1025-1051.	1.8	15
317	From the Clinic to the Bench and Back Again in One Dog Year: How a Cross-Species Pipeline to Identify New Treatments for Sarcoma Illuminates the Path Forward in Precision Medicine. Frontiers in Oncology, 2020, 10, 117.	1.3	18
318	Patient-derived tumor-like cell clusters for drug testing in cancer therapy. Science Translational Medicine, 2020, 12, .	5.8	39
319	The Unmet Needs of the Diagnosis, Staging, and Treatment of Gastrointestinal Tumors. Seminars in Nuclear Medicine, 2020, 50, 389-398.	2.5	5
320	When, why and how tumour clonal diversity predicts survival. Evolutionary Applications, 2020, 13, 1558-1568.	1.5	11
321	Detecting heterogeneity in and between breast cancer cell lines. Cancer Convergence, 2020, 4, 1.	8.0	39
322	â€œAll-in-Oneâ€•Silver Nanoprism Platform for Targeted Tumor Theranostics. ACS Applied Materials & Interfaces, 2020, 12, 11329-11340.	4.0	23
323	Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications. Advanced Functional Materials, 2020, 30, 1910402.	7.8	28
324	Comparative Molecular Life History of Spontaneous Canine and Human Gliomas. Cancer Cell, 2020, 37, 243-257.e7.	7.7	59
325	Establishment and Characterization of a Brca1â^'/â^', p53â^'/â^' Mouse Mammary Tumor Cell Line. International Journal of Molecular Sciences, 2020, 21, 1185.	1.8	10
326	Guidelines for cell-type heterogeneity quantification based on a comparative analysis of reference-free DNA methylation deconvolution software. BMC Bioinformatics, 2020, 21, 16.	1.2	34
327	Natural selection between two games with applications to game theoretical models of cancer. , 2020, , 279-290.		0
328	Spatial heterogeneity of oxygenation and haemodynamics in breast cancer resolved in vivo by conical multispectral optoacoustic mesoscopy. Light: Science and Applications, 2020, 9, 57.	7.7	45

#	Article	IF	Citations
329	Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell, 2020, 37, 584-598.e11.	7.7	96
330	Advancing Cancer Research and Medicine with Single-Cell Genomics. Cancer Cell, 2020, 37, 456-470.	7.7	187
331	A bi-adjuvant nanovaccine that potentiates immunogenicity of neoantigen for combination immunotherapy of colorectal cancer. Science Advances, 2020, 6, eaaw6071.	4.7	152
332	How Non-invasive in vivo Cell Tracking Supports the Development and Translation of Cancer Immunotherapies. Frontiers in Physiology, 2020, 11, 154.	1.3	27
333	Tunneling Nanotubes and Tumor Microtubes in Cancer. Cancers, 2020, 12, 857.	1.7	76
334	Cellular community detection for tissue phenotyping in colorectal cancer histology images. Medical Image Analysis, 2020, 63, 101696.	7.0	87
335	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology, 2021, 73, 14-26.	3.6	66
336	Comparison of amide proton transfer imaging and magnetization transfer imaging in revealing glioma grades and proliferative activities: a histogram analysis. Neuroradiology, 2021, 63, 685-693.	1.1	4
337	Blueprint for cancer research: Critical gaps and opportunities. Ca-A Cancer Journal for Clinicians, 2021, 71, 107-139.	157.7	47
338	Genomic and phenotypic heterogeneity in prostate cancer. Nature Reviews Urology, 2021, 18, 79-92.	1.9	215
339	Design and Evaluation of Rhein-Based MRI Contrast Agents for Visualization of Tumor Necrosis Induced by Combretastatin A-4 Disodium Phosphate. Molecular Imaging and Biology, 2021, 23, 220-229.	1.3	2
340	Cancer Biology, Epidemiology, and Treatment in the 21st Century: Current Status and Future Challenges From a Biomedical Perspective. Cancer Control, 2021, 28, 107327482110387.	0.7	8
341	Intratumor heterogeneity of breast cancer detected by epialleles shows association with hypoxic microenvironment. Theranostics, 2021, 11, 4403-4420.	4.6	5
343	An epistasis and heterogeneity analysis method based on maximum correlation and maximum consistence criteria. Mathematical Biosciences and Engineering, 2021, 18, 7711-7726.	1.0	0
344	Integrated Genomic and Transcriptomic Analysis reveals key genes for predicting dual-phenotype Hepatocellular Carcinoma Prognosis. Journal of Cancer, 2021, 12, 2993-3010.	1.2	5
345	Circulating tumour DNA in Bâ€cell lymphomas: current state and future prospects. British Journal of Haematology, 2021, 193, 867-881.	1.2	11
346	Biophysical informatics approach for quantifying phenotypic heterogeneity in cancer cell migration in confined microenvironments. Bioinformatics, 2021, , .	1.8	9
347	Lymphoma Heterogeneity Unraveled by Single-Cell Transcriptomics. Frontiers in Immunology, 2021, 12, 597651.	2.2	9

#	Article	IF	Citations
348	Quartile histogram assessment of glioma malignancy using high bâ€value diffusion MRI with a continuousâ€time randomâ€walk model. NMR in Biomedicine, 2021, 34, e4485.	1.6	15
349	Understanding breast cancer heterogeneity through non-genetic heterogeneity. Breast Cancer, 2021, 28, 777-791.	1.3	6
350	Roles of phenotypic heterogeneity and microenvironment feedback in early tumor development. Physical Review E, 2021, 103, 032407.	0.8	9
351	The potential of long noncoding RNAs for precision medicine in human cancer. Cancer Letters, 2021, 501, 12-19.	3.2	18
353	Morphodynamic signatures of MDA-MB-231 single cells and cell doublets undergoing invasion in confined microenvironments. Scientific Reports, 2021, 11, 6529.	1.6	15
354	Cell-Free DNA for the Management of Classical Hodgkin Lymphoma. Pharmaceuticals, 2021, 14, 207.	1.7	9
355	Singleâ€Cell Sequencing Methodologies: From Transcriptome to Multiâ€Dimensional Measurement. Small Methods, 2021, 5, e2100111.	4.6	17
356	Machine learning-based investigation of the cancer protein secretory pathway. PLoS Computational Biology, 2021, 17, e1008898.	1.5	7
357	Optimal Bayesian supervised domain adaptation for RNA sequencing data. Bioinformatics, 2021, 37, 3212-3219.	1.8	1
358	Breast cancer as an example of tumour heterogeneity and tumour cell plasticity during malignant progression. British Journal of Cancer, 2021, 125, 164-175.	2.9	177
359	Epigenome Chaos: Stochastic and Deterministic DNA Methylation Events Drive Cancer Evolution. Cancers, 2021, 13, 1800.	1.7	13
360	Characterizing genetic intra-tumor heterogeneity across 2,658 human cancer genomes. Cell, 2021, 184, 2239-2254.e39.	13.5	260
361	Providing an optimized model to detect driver genes from heterogeneous cancer samples using restriction in subspace learning. Scientific Reports, 2021, 11, 9171.	1.6	0
362	Unique evolutionary trajectories of breast cancers with distinct genomic and spatial heterogeneity. Scientific Reports, 2021, 11, 10571.	1.6	0
364	How to manage synchronous endometrial and ovarian cancer patients?. BMC Cancer, 2021, 21, 489.	1.1	7
365	Protocol for Creating Antibodies with Complex Fluorescence Spectra. Bioconjugate Chemistry, 2021, 32, 1156-1166.	1.8	2
366	Enzyme/GSH dual-responsive biodegradable nanohybrid for spatiotemporally specific photodynamic and hypoxia-augmented therapy against tumors. International Journal of Pharmaceutics, 2021, 603, 120730.	2.6	11
367	Smart Nanoparticles for Chemo-Based Combinational Therapy. Pharmaceutics, 2021, 13, 853.	2.0	22

#	Article	IF	Citations
368	Identifying Key Somatic Copy Number Alterations Driving Dysregulation of Cancer Hallmarks in Lower-Grade Glioma. Frontiers in Genetics, 2021, 12, 654736.	1.1	6
369	Aza-BODIPY-based phototheranostic nanoagent for tissue oxygen auto-adaptive photodynamic/photothermal complementary therapy. Nano Research, 2022, 15, 716-727.	5.8	18
370	Radiogenomics in brain, breast, and lung cancer: opportunities and challenges. Journal of Medical Imaging, 2021, 8, 031907.	0.8	5
371	A Bayesian nonparametric model for inferring subclonal populations from structured DNA sequencing data. Annals of Applied Statistics, 2021, 15, 925-951.	0.5	0
372	Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 593.	1.1	11
373	Single-cell RNA sequencing in human lung cancer: Applications, challenges, and pathway towards personalized therapy. Journal of the Chinese Medical Association, 2021, 84, 563-576.	0.6	7
374	Overcoming resistance to BRAFV600E inhibition in melanoma by deciphering and targeting personalized protein network alterations. Npj Precision Oncology, 2021, 5, 50.	2.3	14
375	Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Journal of Hepatology, 2021, 75, 1397-1408.	1.8	133
376	The protein corona and its effects on nanoparticle-based drug delivery systems. Acta Biomaterialia, 2021, 129, 57-72.	4.1	95
377	Comparative analysis of clonal evolution among patients with right- and left-sided colon and rectal cancer. IScience, 2021, 24, 102718.	1.9	9
378	A Multimodal Affinity Fusion Network for Predicting the Survival of Breast Cancer Patients. Frontiers in Genetics, 2021, 12, 709027.	1.1	4
379	Smallâ€Molecule Prodrug Nanoassemblies: An Emerging Nanoplatform for Anticancer Drug Delivery. Small, 2021, 17, e2101460.	5.2	87
382	Deep Subspace Mutual Learning for cancer subtypes prediction. Bioinformatics, 2021, 37, 3715-3722.	1.8	17
383	Heterogeneous microenvironmental stiffness regulates pro-metastatic functions of breast cancer cells. Acta Biomaterialia, 2021, 131, 326-340.	4.1	56
384	Circulating Tumor DNA in Lymphoma: Principles and Future Directions. Blood Cancer Discovery, 2022, 3, 5-15.	2.6	25
385	Conquering the Hypoxia Limitation for Photodynamic Therapy. Advanced Materials, 2021, 33, e2103978.	11.1	262
386	Evolution of the Tumor Microenvironment toward Immune-Suppressive Seclusion during Brain Metastasis of Breast Cancer: Implications for Targeted Therapy. Cancers, 2021, 13, 4895.	1.7	11
387	New confinement index and new perspective for comparing countries - COVID-19. Computer Methods and Programs in Biomedicine, 2021, 210, 106346.	2.6	1

#	Article	IF	Citations
388	Multifunctional biomaterials that modulate oxygen levels in the tumor microenvironment. Cancer Letters, 2021, 521, 39-49.	3.2	8
389	Recent advances in gene therapy for cancer theranostics. Current Opinion in Biomedical Engineering, 2021, 20, 100300.	1.8	2
390	Epigenetic heterogeneity in primary bone cancers. , 2022, , 431-445.		0
391	Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management. Biomolecules, 2021, 11, 136.	1.8	20
392	Technological challenges of theranostics in oncology. , 2021, , 307-344.		2
393	Capturing Tumor Heterogeneity and Clonal Evolution by Circulating Tumor DNA Profiling. Recent Results in Cancer Research, 2020, 215, 213-230.	1.8	15
400	Multiplexed immunofluorescence delineates proteomic cancer cell states associated with metabolism. JCI Insight, 2016, 1, .	2.3	41
401	Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. Journal of Experimental and Clinical Cancer Research, 2020, 39, 22.	3.5	50
402	A pan-cancer analysis of the clinical and genetic portraits of somatostatin receptor expressing tumor as a potential target of peptide receptor imaging and therapy. EJNMMI Research, 2020, 10, 42.	1.1	11
403	A single cell atlas of the human liver tumor microenvironment. Molecular Systems Biology, 2020, 16, e9682.	3.2	99
404	Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 2017, 8, 108463-108479.	0.8	8
405	Autologous reconstitution of human cancer and immune system in vivo. Oncotarget, 2017, 8, 2053-2068.	0.8	20
406	Stroma-derived but not tumor ADAMTS1 is a main driver of tumor growth and metastasis. Oncotarget, 2016, 7, 34507-34519.	0.8	16
407	Centrosome aberrations and chromosome instability contribute to tumorigenesis and intra-tumor heterogeneity. Journal of Cancer Metastasis and Treatment, 2018, 4, 43.	0.5	23
408	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. Journal of Cancer Metastasis and Treatment, 2019, 2019, .	0.5	11
409	Single-cell RNA-seq reveals the immune escape and drug resistance mechanisms of mantle cell lymphoma. Cancer Biology and Medicine, 2020, 17, 726-739.	1.4	25
410	Macrophage Flipping from Foe to Friend: A Matter of Interest in Breast Carcinoma Heterogeneity Driving Drug Resistance. Current Cancer Drug Targets, 2019, 19, 189-198.	0.8	7
411	Association Between Interleukin-10 Receptors and the CD45-Immunophenotype of Central Nervous System Tumors: A Preliminary Study. , 2017, 37, 5777-5783.		7

#	Article	IF	Citations
412	BRCA1 Promoter Methylation and Clinicopathological Characteristics in Sporadic Breast Cancer Patients in Indonesia. Asian Pacific Journal of Cancer Prevention, 2018, 19, 2643-2649.	0.5	8
413	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Annals of Breast Cancer and Therapy, 2020, 4, 48-57.	0.8	11
414	Pointwise mutual information quantifies intratumor heterogeneity in tissue sections labeled with multiple fluorescent biomarkers. Journal of Pathology Informatics, 2016, 7, 47.	0.8	18
415	Emerging techniques in single-cell epigenomics and their applications to cancer research. , 2018, 1, .		23
416	Aneuploidy in stem cells. World Journal of Stem Cells, 2016, 8, 216.	1.3	14
417	Estrogen receptor alpha gene amplification in breast cancer: 25 years of debate. World Journal of Clinical Oncology, 2016, 7, 160.	0.9	21
418	Acute Myeloid Leukemia: Is That All There Is?. Cureus, 2018, 10, e3198.	0.2	4
419	Assessment of 5-Aminolevulinic Acid-Mediated Photodynamic Therapy on Bone Metastases: An in Vitro Study. Biology, 2021, 10, 1020.	1.3	0
423	Tumor Heterogeneity and Resistance to Targeted Therapies in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 1-24.	0.1	0
428	Metabolic Dysregulation in Environmental Carcinogenesis and Toxicology. , 0, , 511-606.		0
430	Pushing indium phosphide quantum dot emission deeper into the near infrared. , 2018, , .		0
432	Induction of Apoptotic Death and Cell Cycle Arrest in HeLa Cells by Extracellular Factors of Breast Cancer Cells. Asian Pacific Journal of Cancer Prevention, 2018, 19, 3307-3316.	0.5	8
437	Precision Medicine and Complexity. , 2020, , 149-173.		0
443	Ambient Biobanking Solutions for Whole Blood Sampling, Transportation, and Extraction. , 0, , .		0
444	The Epithelial and Stromal Immune Microenvironment in Gastric Cancer: A Comprehensive Analysis Reveals Prognostic Factors with Digital Cytometry. Cancers, 2021, 13, 5382.	1.7	2
445	Heterogeneity of Circulating Tumor Cellâ€“Associated Genomic Gains in Breast Cancer and Its Association with the Host Immune Response. Cancer Research, 2021, 81, 6196-6206.	0.4	5
446	Basic Biology of Brain Metastasis. , 2020, , 19-35.		0
448	Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. Cancers, 2021, 13, 5524.	1.7	15

#	Article	IF	Citations
455	Conquering the challenges of genotypic and phenotypic tumor heterogeneity to realize the promise of personalized cancer therapy: the role of academia. Transactions of the American Clinical and Climatological Association, 2017, 128, 169-179.	0.9	1
457	A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment. Scientific Reports, 2021, 11, 22502.	1.6	23
458	Precise Control of Shape-Variable Nanomicelles in Nanofibers Reveals the Enhancement Mechanism of Passive Delivery. ACS Applied Materials & Interfaces, 2021, 13, 54715-54726.	4.0	3
460	Novel technologies in cfDNA analysis and potential utility in clinic. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 708-718.	0.7	5
461	Irradiation conditioning of adjuvanted, autologous cancer cell membrane nanoparticle vaccines. Chemical Engineering Journal, 2022, 433, 134437.	6.6	9
462	Identification of rare cell populations in autofluorescence lifetime image data. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2022, 101, 497-506.	1.1	7
465	Inflammation and Myeloid Cells in Cancer Progression and Metastasis. Frontiers in Cell and Developmental Biology, 2021, 9, 759691.	1.8	12
466	Understanding sarcoma drug resistance one cell at a time. Cancer Drug Resistance (Alhambra, Calif), 2022, 5, 90-92.	0.9	0
467	A Stochastic Binary Model for the Regulation of Gene Expression to Investigate Responses to Gene Therapy. Cancers, 2022, 14, 633.	1.7	3
468	Early Predictor Tool of Disease Using Label-Free Liquid Biopsy-Based Platforms for Patient-Centric Healthcare. Cancers, 2022, 14, 818.	1.7	6
469	The combination of MnO₂@Lipo-coated gefitinib and bevacizumab inhibits the development of non-small cell lung cancer. Drug Delivery, 2022, 29, 466-477.	2.5	5
470	Analyzing Association Between Expression Quantitative Trait and CNV for Breast Cancer Based on Gene Interaction Network Clustering and Group Sparse Learning. Current Bioinformatics, 2022, 17, 358-368.	0.7	1
471	Multi-level feature fusion for nucleus detection in histology images using correlation filters. Computers in Biology and Medicine, 2022, 143, 105281.	3.9	5
472	Fluorescence imaging of tumor immune contexture in immune checkpoint blockade therapy. International Immunopharmacology, 2022, 106, 108617.	1.7	5
473	Branched Polymerâ€Based Redox/Enzymeâ€Activatable Photodynamic Nanoagent to Trigger STINGâ€Dependent Immune Responses for Enhanced Therapeutic Effect. Advanced Functional Materials, 2022, 32, .	7.8	59
474	MDICC: novel method for multi-omics data integration and cancer subtype identification. Briefings in Bioinformatics, 2022, 23, .	3.2	15
475	A â€œSelfâ€Checkingâ€•pH/Viscosityâ€Activatable NIRâ€II Molecule for Realâ€Time Evaluation of Photothermal Therapy Efficacy. Angewandte Chemie - International Edition, 2022, 61, .	7.2	42
476	A â€œSelfâ€Checkingâ€•pH/Viscosityâ€Activatable NIRâ€II Molecule for Realâ€Time Evaluation of Photothermal Therapy Efficacy. Angewandte Chemie, 2022, 134, .	1.6	2

#	Article	IF	Citations
477	Cell-type heterogeneity: Why we should adjust for it in epigenome and biomarker studies. Clinical Epigenetics, 2022, 14, 31.	1.8	18
478	The microbiome and precision oncology: an emerging paradigm in anticancer therapy. Critical Reviews in Microbiology, 2022, 48, 770-783.	2.7	1
480	Artificial Nanoplatelets Depend on Size for Precisely Inducing Thrombosis in Tumor Vessels. Small Methods, 2022, 6, e2101474.	4.6	2
481	Leukemic stem cell signatures in Acute myeloid leukemia- targeting the Guardians with novel approaches. Stem Cell Reviews and Reports, 2022, 18, 1756-1773.	1.7	7
482	Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation. Pharmaceutics, 2022, 14, 728.	2.0	33
483	Intratumor Heterogeneity and Antitumor Immunity Shape One Another Bidirectionally. Clinical Cancer Research, 2022, 28, 2994-3001.	3.2	15
484	Lift the curtain on long non-coding RNAs in hematological malignancies: Pathogenic elements and potential targets. Cancer Letters, 2022, 536, 215645.	3.2	7
495	Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance. International Journal of Biological Sciences, 2022, 18, 3019-3033.	2.6	54
496	Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA. PLoS ONE, 2022, 17, e0267389.	1.1	7
497	Infrared Laser Ablation Microsampling for Small Volume Proteomics. Journal of the American Society for Mass Spectrometry, 2022, , .	1.2	1
498	New classification for advanced breast cancer patients experiencing disease progression during salvage treatment: a single-center retrospective cohort study. Annals of Translational Medicine, 2021, .	0.7	0
499	Colorectal Cancer Patientâ€Derived 2D and 3D Models Efficiently Recapitulate Interâ€and Intratumoral Heterogeneity. Advanced Science, 2022, 9, .	5.6	10
501	Molecular alterations associated with improved outcome in patients with glioblastoma treated with Tumor-Treating Fields. Neuro-Oncology Advances, 2022, 4, .	0.4	4
502	Patient-Derived Organoid Model in the Prediction of Chemotherapeutic Drug Response in Colorectal Cancer. ACS Biomaterials Science and Engineering, 2022, 8, 3515-3525.	2.6	3
503	Role of Artificial Intelligence in Radiogenomics for Cancers in the Era of Precision Medicine. Cancers, 2022, 14, 2860.	1.7	38
504	Scales of Cancer Evolution: Selfish Genome or Cooperating Cells?. Cancers, 2022, 14, 3253.	1.7	3
505	Clinical application and prospect of MRD evaluation in lung cancer based on ctDNA level: A review. Tumori, 0, , 030089162211019.	0.6	0
506	Applications of singleâ€cell multiâ€omics sequencing in deep understanding of brain diseases. Clinical and Translational Discovery, 2022, 2, .	0.2	0

#	Article	IF	Citations
507	Histologically resolved multiomics enables precise molecular profiling of human intratumor heterogeneity. PLoS Biology, 2022, 20, e3001699.	2.6	6
508	A Detailed Overview About the Single-Cell Analyses of Solid Tumors Focusing on Colorectal Cancer. Pathology and Oncology Research, 0, 28, .	0.9	5
509	InÂvivo imaging with SERS nanoprobes. , 2022, , 199-235.		0
510	Cancer cell states recur across tumor types and form specific interactions with the tumor microenvironment. Nature Genetics, 2022, 54, 1192-1201.	9.4	130
512	Four types of <scp>RNA</scp> modification writers predict the prognosis of prostate cancer. Andrologia, 2022, 54, .	1.0	1
513	Evolution of intra-tumoral heterogeneity across different pathological stages in papillary thyroid carcinoma. Cancer Cell International, 2022, 22, .	1.8	7
514	Mathematical characterization of population dynamics in breast cancer cells treated with doxorubicin. Frontiers in Molecular Biosciences, 0, 9, .	1.6	5
515	Expression Analysis of Ligand-Receptor Pairs Identifies Cell-to-Cell Crosstalk between Macrophages and Tumor Cells in Lung Adenocarcinoma. Journal of Immunology Research, 2022, 2022, 1-15.	0.9	2
516	EPM2A acts as a protective factor in prostate cancer, evidence from a real-world patient cohort. Frontiers in Pharmacology, 0, 13, .	1.6	0
517	CSMD1 Shows Complex Patterns of Somatic Copy Number Alterations and Expressions of mRNAs and Target Micro RNAs in Esophageal Squamous Cell Carcinoma. Cancers, 2022, 14, 5001.	1.7	1
518	Multiâ€Targeting Nanoâ€Systems Targeting Heterogenous Cancer Cells for Therapeutics and Biomarker Detection. Advanced Healthcare Materials, 0, , 2202155.	3.9	2
519	Validation of the DNA Methylation Landscape of TFF1/TFF2 in Gastric Cancer. Cancers, 2022, 14, 5474.	1.7	2
520	Cervical cancer heterogeneity: a constant battle against viruses and drugs. Biomarker Research, 2022, 10, .	2.8	10
521	Intratumor heterogeneity is associated with less CD8+ T cell infiltration and worse survival in patients with small cell lung cancer. Clinical and Translational Oncology, 2023, 25, 1043-1052.	1.2	1
523	A review of effects of atorvastatin in cancer therapy. , 2023, 40, .		4
524	Integrated single-cell transcriptome analysis of CD34â€‰+â€‰enriched leukemic stem cells revealed intra- and inter-patient transcriptional heterogeneity in pediatric acute myeloid leukemia. Annals of Hematology, 2023, 102, 73-87.	0.8	3
525	Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell, 2023, 41, 210-225.e5.	7.7	32
526	In-silico study of asymmetric remodeling of tumors in response to external biochemical stimuli. Scientific Reports, 2023, 13, .	1.6	1

#	Article	IF	Citations
527	Single-Cell Transcriptomics Unveils the Dedifferentiation Mechanism of Lung Adenocarcinoma Stem Cells. International Journal of Molecular Sciences, 2023, 24, 482.	1.8	2
528	Mathematical Modeling of Spherical Shell-Type Pattern of Tumor Invasion. Symmetry, 2023, 15, 283.	1.1	2
529	Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Measuring Perfusion in Pancreatic Ductal Adenocarcinoma and Different Tumor Grade: A Preliminary Single Center Study. Diagnostics, 2023, 13, 521.	1.3	1
530	Integrating multi-type aberrations from DNA and RNA through dynamic mapping gene space for subtype-specific breast cancer driver discovery. PeerJ, 0, 11, e14843.	0.9	2
531	Current and Emerging Techniques for Diagnosis and MRD Detection in AML: A Comprehensive Narrative Review. Cancers, 2023, 15, 1362.	1.7	1
532	Pancreatic Cancer Presents Distinct Nanomechanical Properties During Progression. Annals of Biomedical Engineering, 2023, 51, 1602-1615.	1.3	7
533	Who dictates and when: Genetic and epigenetic dictatorships in breast cancer response and resistance to therapy. , 2023, , 49-73.		0
534	rcCAE: a convolutional autoencoder method for detecting intra-tumor heterogeneity and single-cell copy number alterations. Briefings in Bioinformatics, 2023, 24, .	3.2	2
535	Comprehensive analysis of the role of ICOS (CD278) in pan-cancer prognosis and immunotherapy. BMC Cancer, 2023, 23, .	1.1	6
537	Physics-based tissue simulator to model multicellular systems: A study of liver regeneration and hepatocellular carcinoma recurrence. PLoS Computational Biology, 2023, 19, e1010920.	1.5	0
538	Single-Cell and Transcriptome-Based Immune Cell-Related Prognostic Model in Clear Cell Renal Cell Carcinoma. Journal of Oncology, 2023, 2023, 1-15.	0.6	0
539	Current status of Cancer Nanotheranostics: Emerging strategies for cancer management. Nanotheranostics, 2023, 7, 368-379.	2.7	4
540	Biomechanical and biochemical assessment of YB-1 expression in A375 melanoma cell line: Exploratory study. Frontiers in Molecular Medicine, 0, 3, .	0.6	1
549	Classification and Evolution of Tumor Ecosystem. , 2023, , 655-674.		0
552	Nanoprobe-based molecular imaging for tumor stratification. Chemical Society Reviews, 2023, 52, 6447-6496.	18.7	7
569	Regulating metalloimmunology with nanomedicine for cancer therapy. Nano Research, 2023, 16, 13164-13181.	5.8	0
571	State-of-the-art mass spectrometry imaging applications in biomedical research. Analyst, The, 2023, 148, 6161-6187.	1.7	1
585	Vitamin D and cancer. Advances in Food and Nutrition Research, 2024, , .	1.5	0

#	Article	IF	Citations